Infertility
Conditions
Keywords
IVF/ICSI cycles, poor responders, ultrashort flare protocol, antagonist protocol
Brief summary
To evaluate the effect of oestradiol pre-treatment in a combined ultrashort flare GnRH agonist /GnRH antagonist protocol
Detailed description
The combined ultrashort flare GnRH agonist /GnRH antagonist protocol during COH cycle resulted in a significantly higher clinical pregnancy rate in patients with poor embryo quality, with repeated IVF failures and in poor responders. This is a protocol combining the effect of the microdose flare on endogenous FSH release with the benefit of an immediate LH suppression of the GnRH antagonist. A major disadvantage of the use of a GnRH antagonist protocol is the limitation for programming cycles, as the drugs administration is started on day 2 of the menstrual cycle and is strictly followed until the hCG criteria are met. The purpose of the study is to perform oestradiol pre-treatment with the combined ultrashort flare GnRH agonist /GnRH antagonist protocol aiming to 1. better programme an antagonist cycle and 2. improve the IVF outcome parameters, from the production of more follicles / oocytes up to the rise in live birth rates.
Interventions
PROCEDUREOestradiol pre-treatment and combination of GnRH agonist/antagonist protocol
PROCEDUREGnRH agonist or antagonist protocol without oestradiol pre-treatment
Sponsors
National and Kapodistrian University of Athens
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 44 Years
Healthy volunteers
No
Inclusion criteria
* Patients with poor or no response in previous COH for IVF cycles * Patients with AMH \< 1 and/or FSH \>12 * Poor quality of embryos in previous cycles * Age of patients up to 44 years
Exclusion criteria
* Patients with normal ovarian reserve * Patients with sonographically detected hydrosalpinges * Presence of intramural fibroid distorting the endometrial cavity or submucous myoma or Asherman's syndrome * Women with thrombofilia disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate | 2 years |
| Live birth rate | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Top embryo quality at day 2 | 2 years |
| Biochemical pregnancy | 2 years |
| Miscarriage rate | 2 years |
| Ectopic pregnancy | 2 years |
| Number of oocytes retrieved | 2 years |
Other
| Measure | Time frame |
|---|---|
| Positive Pregnancy Test | 2 years |
Countries
Greece
Outcome results
None listed